Genflow Reports Positive Interim Data for SIRT6 Gene Therapy in Aged Dogs

Genflow Biosciences Plc ( (GB:GENF) ) has provided an announcement.

Genflow Biosciences has reported positive preliminary interim results from its SLAB clinical trial testing its proprietary SIRT6 centenarian gene therapy in 24 aged beagle dogs. The randomized, blinded study found that all treatment groups showed better survival than controls during the dosing period, with no adverse events and an encouraging safety and tolerability profile in older companion animals.

Dogs receiving the gene therapy also showed improvements versus controls in quality of life, muscle mass preservation, frailty index, and coat condition, countering typical age-related decline. Key biological endpoints, including methylation clock-based biological age and muscle biopsy histology, are still being analysed, and the company expects full data within about two months to support ongoing discussions with potential animal health partners.

Genflow believes the consistent positive signals across survival and functional measures strengthen the case for its SIRT6 platform as a first-in-class approach to addressing age-related decline in companion animals. The company is proceeding with a follow-up phase to assess durability of benefits and age-related disease onset, using the emerging dataset to advance potential licensing, co-development, and commercialisation deals in the companion animal market.

The most recent analyst rating on (GB:GENF) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Genflow Biosciences Plc stock, see the GB:GENF Stock Forecast page.

Spark’s Take on GB:GENF Stock

According to Spark, TipRanks’ AI Analyst, GB:GENF is a Neutral.

The score is primarily constrained by weak financial performance (no revenue, ongoing losses, continued cash burn) and a weakened balance sheet with negative equity. Technicals are moderately supportive given the price trend above key moving averages, but valuation remains pressured due to losses and no dividend support.

To see Spark’s full report on GB:GENF stock, click here.

More about Genflow Biosciences Plc

Genflow Biosciences Plc is a UK-headquartered biotechnology company with R&D operations in Belgium, focused on developing gene therapies for age-related diseases in order to extend healthy lifespan and reduce the burden of an aging population. Its lead candidate, GF-1002, delivers a centenarian variant of the SIRT6 gene and is being evaluated in a 12-month proof-of-concept trial in aged dogs, alongside plans to study its potential in treating MASH, a prevalent chronic liver disease lacking effective therapies.

Average Trading Volume: 1,774,816

Technical Sentiment Signal: Buy

Current Market Cap: £10.36M

For detailed information about GENF stock, go to TipRanks’ Stock Analysis page.